10×10 Capsules
Overview
RPZNAX-DSR delivers prompt action and fast relief in acid-peptic disorders through a powerful dual-component capsule. Rabeprazole Sodium 20mg (enteric-coated) provides fast and complete inhibition of acid secretion, while Domperidone 30mg (sustained-release) effectively controls nausea, vomiting, and reflux — making it the complete solution for peptic disorders.
Described as "The Powerful Control of Acid-Peptic Disorders", this DSR (Delayed & Sustained Release) capsule is clinically optimised to tackle both the acid and motility components of GERD and dyspepsia in a single once-daily dose.
Indications
- Esophagitis and Gastroesophageal Reflux Disease (G.E.R.D.)
- Nausea & Vomiting of various aetiologies
- Dyspepsia (functional and organic)
- Heartburn — day-time and night-time
- Hyperacidity and acid-peptic disorders
- Adjunct therapy in H. pylori eradication regimens
Esophagitis
G.E.R.D.
Nausea & Vomiting
Dyspepsia
Heart Burn
Hyperacidity
Mechanism of Action
RABEPRAZOLE
- Fast & complete inhibition of gastric acid secretion via irreversible H+/K+-ATPase blockade
- Significant reduction in both day-time and night-time heartburn
- Enteric-coating (EC) ensures optimal duodenal absorption, bypassing gastric acid degradation
DOMPERIDONE
- Effectively controls nausea & vomiting through peripheral dopamine D2-receptor antagonism
- Reduces reflux by increasing lower oesophageal sphincter tone
- SR formulation provides sustained prokinetic action over 8–12 hours without CNS side effects
Dosage & Administration
- Adults: 1 capsule once daily, 30 minutes before breakfast
- Duration: 4–8 weeks for GERD; reassess after initial course
- Swallow capsule whole — do not open, crush, or chew
- Elderly / Hepatic impairment: Use with caution; reduce dose if required
- Not recommended in children under 12 years
Contraindications
- Hypersensitivity to rabeprazole, domperidone, or any excipient
- Conditions where cardiac conduction could be impaired (QT prolongation risk)
- Co-administration with strong CYP3A4 inhibitors (e.g., ketoconazole, erythromycin)
- Moderate-to-severe hepatic impairment
- Prolactin-releasing pituitary tumour (prolactinoma)
- Pregnancy and lactation — not recommended without specialist advice
